




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12P 41/00, 13/00, C07D 209/52</b>	<b>A1</b>	(11) International Publication Number: <b>WO 99/10519</b> (43) International Publication Date: <b>4 March 1999 (04.03.99)</b>
(21) International Application Number: <b>PCT/EP98/05291</b> (22) International Filing Date: <b>20 August 1998 (20.08.98)</b> (30) Priority Data: <b>9717928.7</b> <b>22 August 1997 (22.08.97)</b> <b>GB</b> (71) Applicant (for all designated States except US): <b>GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>DAWSON, Michael, John [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). MAHMOUDIAN, Mahmond [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). WALLIS, Christopher, John [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).</b> (74) Agent: <b>PETT, Christopher, P.; Frank B. Dehn &amp; Co., 179 Queen Victoria Street, London EC4V 4EL (GB).</b>		(81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: <b>PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED N-DERIVATISED LACTAMS</b>  <div style="text-align: center;">  <div style="margin-left: 100px;">(IV)</div> </div> (57) Abstract  The present invention relates to a process for the production of substantially enantiomerically pure intermediates of formula (IV), wherein P is an activating and protecting group, from their racemates by treating the mixture with an acylase enzyme derived from <i>Bacillus</i> sp..		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

Process for preparing enantiomerically enriched N-derivatised lactams

5


The present invention relates to a process for the preparation of enantiomerically enriched N-derivatised (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-ones.

10

Abacavir, a 2-aminopurine nucleoside analogue with the following structure (I)

15

20



25

known from EP 0434 450, has potent activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

30


There exists a need to synthesise large quantities of abacavir for clinical trials. In the future, once abacavir has been approved by the national medicine regulatory agencies, large quantities of abacavir will also be required for sale as a prescription medicine for the treatment of HIV infections.

35

An important step in the manufacture of abacavir is the preparation of an enantiomerically pure substituted cyclopentene ring. Existing methods are known which commence from a lactam of formula (II)


CONFIRMATION COPY

- 2 -



(II)

EP-A-0424064 describes a process wherein the racemic lactam (II) prepared by the reaction of cyclopentadiene with tosyl cyanide, can be reacted with lactamases that will give a single *cis* enantiomer, or a mixture of *cis* enantiomers which is enriched with respect to one of the enantiomers, of the ring-opened compound (III)




(III)

together with unreacted lactam which is enantiomerically enriched with respect to one or other enantiomer.

We have now developed a high yielding and cost effective process for the production of substantially enantiomerically pure intermediates of formula (IV)

25



(IV)

30

wherein P is an activating and protecting group

from their racemates.


35

We have found that derivatisation of the lactam nitrogen atom in the compound of formula (II) with a group P [as

- 3 -

in formula (V) below] activates the lactam bond for hydrolysis. We have surprisingly found that enzymes more readily obtainable than those described in EP-A-0424064 and which appear, under normal conditions, to have no activity in relation to the lactam of formula (II) described in EP-A-0424064 can be used to produce compounds of formula (IV).

According to one aspect of the present invention, therefore, we provide a process for the enantiomeric resolution of a racemic mixture of N-protected ( $\pm$ ) 2-azabicyclo[2.2.1]hept-5-en-3-one (V)



20 wherein P is an activating and protecting group, to yield substantially enantiomerically pure N-protected (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one (IV) by treating the mixture with an acylase enzyme.

25 According to a further aspect of the present invention, we provide a process for the preparation of substantially enantiomerically pure N-protected (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one of formula (IV), above, wherein P is an activating and protecting group, wherein a racemic mixture of N-protected ( $\pm$ ) 2-azabicyclo[2.2.1]hept-5-en-3-one of formula (V), above, wherein P is an activating or protecting group, is treated with an acylase enzyme and the unreacted enantiomer of formula (IV) is isolated from the reaction mixture by conventional techniques.

35

It is preferred that the activating / protecting group

- 4 -

is an acyl or substituted oxycarbonyl group. Preferred acyl groups include formyl or lower alkanoyl (having e.g. 1 to 4 carbon atoms in the alkyl portion), especially an acetyl group. Preferred substituted  
5 oxycarbonyl groups will be of the formula  $\text{ROC(O)-}$ , wherein R may be an alkyl or aralkyl group. A preferred alkyl group is tert butyl. A possible aralkyl group is benzyl.

10 Since we have also found that substantial deprotection of these acyl-protected compounds can occur under aqueous conditions, it is preferred that the reaction is carried out in a mixture of organic solvent and water. It is preferred to use water miscible organic solvents,  
15 such as cyclic ethers e.g. tetrahydrofuran or 1,4-dioxan. To minimise deprotection it is preferred to use less than 70% water, more preferably around 50% or less (by volume). A mixture of tetrahydrofuran and water of approximately 50:50 (v/v) has been found most suitable.

20 When used as above the reaction may generally take place in a single phase. However, there is no reason why use of an organic solvent to create a bi-phasic system would not also be successful, such as with aromatic  
25 hydrocarbons.

Upon completion of the reaction the unreacted and essentially enantiomerically pure N-protected (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one of formula (IV) can  
30 be isolated from the reaction mixture by conventional techniques, such as solvent extraction.

A number of acylase enzymes have been found which enantioselectively hydrolyse the lactam bond so as to  
35 leave behind the desired isomer. We have found enzymes derived from *Bacillus* sp. in particular to show the right profile of activity. For example, *Subtilisin*

- 5 -

carlsberg (ALTUS) yields N-protected (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one [(IV), P = tert butyl oxycarbonyl] from the racemic mixture (V) in an enantiomeric excess of 73%. Other enzymes include

5 *Bacillus* sp. protease, Neutrase, Novozyme 243, Alcalase and Savinase, and are available commercially from ALTUS and NOVO. Enzymes from other sources which show enantioselective hydrolysis may also be used, such as

10 (Biocatalysts), Flavorpro-192 (peptidase, Biocatalysts), Flavorpro-373 (glutaminase, Biocatalysts), Promod-TP (endopeptidase, Biocatalysts), lipase-CE (*Humicola lanuginosa*, Amano), protease-M (*Aspergillus* sp., Amano),

15 prozyme-6 (*Aspergillus* sp., Amano), lipase PGE (calf root and salivary gland, Amano) and *Aspergillus* sp. acylase (Sigma).

Preferably, the commercially available acylase enzyme Savinase (NOVO) will be used as this has in particular

20 been found to show bioconversion rates of the N-protected (1S,4R)-2-azabicyclo[2.2.1]hept-5-en-3-one suitable for industrial scale applications. Savinase is a proteolytic enzyme prepared by submerged fermentation of an alkalophilic species of *Bacillus*. It is an

25 endoprotease of the serine type. In tests that we have carried out, this enzyme has not shown any ability to hydrolyse a racemic mixture of the unacylated lactam of formula (II), under normal use conditions.

30 Bioconversion of the N-protected (1S,4R)-2-azabicyclo[2.2.1]hept-5-en-3-one will desirably be carried out within a pH range of 6 to 11, preferably 7 to 9. A temperature within the range of 20 to 50°C will preferably be used. It is most preferred to carry out

35 the process at a pH of about 8 and a temperature of about 30°C. A ratio of Savinase:substrate in the range of from 1:1 to 10:1 e.g. from 2:1 to 5:1 (w/w) produces

- 6 -

a clean, rapid reaction. The optimum ratio for a given enzyme can readily be determined by simple experimentation.

5 The starting compounds of formula (V) in which P is *tert* butyloxycarbonyl may be prepared from the corresponding unprotected racemic lactam of formula (II) by methods analogous to those described in Taylor et al., Tet. Asymmetry, 4, p.1117 (1993). Compounds of formula (V)  
10 in which P is formyl or lower alkanoyl may be prepared from the corresponding unprotected racemic lactam of formula (II) by methods as described in T.W. Greene, "Protective Groups in Organic Synthesis", Wiley, New York, 1981, pp. 218-287 and J.F.W. McOmie, "Protective  
15 Groups in Organic Chemistry", Plenum Press, New York, 1973, pp. 43-93, or by analogous methods.

The compound of formula (IV) may readily be converted to the corresponding N-protected amino acid by hydrolysis.  
20 The N-protected amino acid can readily be converted to the corresponding amino alcohol of formula (VI)



by reagents capable of converting carboxylic acids to alcohols, for example lithium aluminium hydride or  
25 borane. Alternatively, the compound of formula (IV) may be directly converted into the corresponding ring-opened amino alcohol of formula (VI) by using sodium borohydride by methods such as described in Tet. Asymm, 4, p. 1117 (1993).

30 The following Examples are intended for illustration only and are not intended to limit the scope of the invention in any way.



Example 1

Several hydrolytic enzymes were screened for the ability to hydrolyse the lactam bond of racemic ( $\pm$ ) tert butyl  
5 3-oxo-2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate [(V),  
P = tert butyl oxycarbonyl] enantioselectively.

Reactions were carried out at room temperature in magnetically-stirred glass vials (4 ml working volume) containing 1 mg/ml of the racemic compound in 50%  
10 tetrahydrofuran: 50% phosphate buffer (v/v) (50 mM, pH 7) at room temperature. Each enzyme was added to give a final concentration of 25 mg/ml. This represents a 25:1 ratio (w:w) of enzyme to substrate which for screening purposes should detect any possible hydrolytic  
15 activity. Flasks with no enzyme served as controls. Periodically, samples were removed and diluted 1:2 with water prior to hplc analysis.

**hplc condition:**

20 Column: Spherisorb C6 (15 x 0.46 cm).  
Isocratic at room temperature at 1 ml/min.  
Mobile phase: 30% (v/v) acetonitrile containing 0.1% (v/v) formic acid.  
Detection wavelength at 200 nm.

25 It was shown that chemical hydrolysis of ( $\pm$ ) tert butyl 3-oxo-2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate was negligible under the reaction conditions. Several enzymes appeared to hydrolyse the racemic compound  
30 enantioselectively to afford (-) (1R, 4S) tert butyl 3-oxo-2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate as evidenced by a negative sign of rotation by chiralyser (HPLC optical rotation detector). Savinase was chosen for further investigation. The reaction mixture,  
35 containing approximately 50% of the starting material, was analysed by chiral hplc and the residual lactam was shown to have an enantiomeric excess of 96.3%.

- 8 -

Furthermore the residual substrate was of the correct absolute configuration for the synthesis of abacavir.

5      **Chiral hplc:**

Column: Chiralcel OD-H(25 x 0.46 cm).

Isocratic at 5°C at 0.5 ml/min.

Mobile phase: 2% (v/v) isopropyl alcohol/heptane.

10      Detection wavelength at 205 nm.

Comparative Example 1

15

A solution containing racemic lactam ( $\pm$ ) 2-azabicyclo [2.2.1]hept-5-en-3-one (II) at 1 mg/ml (4 ml working volume) was treated with Savinase (obtainable from NOVO) (25 mg/ml) in 50% tetrahydrofuran: 50% phosphate buffer (50 mM, pH 7). A flask with no enzyme served as control. Periodically, samples were removed and diluted 1:2 with water prior to hplc analysis.

20

**hplc:**

25

Column: Spherisorb C6 (15 x 0.46 cm).

Isocratic at room temperature at 1 ml/min.

Mobile phase: 4% (v/v) acetonitrile containing 0.1% (v/v) formic acid.

Detection wavelength at 200 nm.

30

There was no reaction after 4 days incubation at room temperature.

- 9 -

Example 2

- Savinase (30g, NOVO) was added to a solution (500 ml) containing 10g of racemic (+) tert butyl 3-oxo-2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate [(V), P = tert butyl oxycarbonyl] in 50:50 (v/v) tetrahydrofuran/50mM phosphate pH 8.0 at 30°C. The reaction was monitored by chiral HPLC for up to 2 days.
- Upon completion of the reaction (ca. 51% conversion, enantiomeric excess of (-) (1R, 4S) tert butyl 3-oxo-2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate >99.8%), the enzyme was filtered and the pH of the clarified solution was raised to 9 with sodium bicarbonate solution. This was then extracted with 3 x 200 ml of cyclohexane. The combined organic phase was back extracted with 100 ml of sodium bicarbonate solution and subsequently washed with 100 ml of brine. Evaporation and drying yielded a free flowing white solid (4.2 g, 84% theory isolated yield). This was identified as (-) (1R, 4S) tert butyl 3-oxo-2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate by NMR; enantiomeric excess >99.8% by chiral HPLC.

Chiral hplc:

- Column: Chiralcel OD-H(25 x 0.46 cm).  
Isocratic, 0.5 ml/min.  
Mobile phase: 2% (v/v) isopropyl alcohol/heptane.  
Detection wavelength at 205 nm.  
Temperature at 5°C

- 10 -

Example 3

A solution of the above (-) (1R, 4S) tert butyl 3-oxo-2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate (3.5 g) in tetrahydrofuran (10 ml) was added to a suspension of sodium borohydride (1.27 g) in methanol (10 ml) and the mixture was stirred at about 20°C for about 18 hours. A further quantity of tetrahydrofuran (10 ml) and sodium borohydride (1.27 g) were added and stirring was continued for about a further 2 hours. 2 Molar hydrochloric acid (30 ml) was cautiously added, followed by toluene (20 ml). The two layers were separated, and the aqueous layer was further extracted with toluene (2 x 25 ml). The combined organic extracts were washed with brine (20 ml), dried over sodium sulfate and evaporated to afford (1R, 4S) (4-hydroxymethyl)-cyclopent-2-en-1-yl carbamic acid tert butyl ester (3.23 g) with an enantiomeric excess of 99.2% by chiral hplc as a pale yellow gum, which was spectroscopically and chromatographically identical to an authentic sample.

Chiral hplc:

Column: Chiralcel OD (25 x 0.46 cm).  
Flow: 1.0 ml/min.  
Mobile phase: 3% (v/v) isopropyl alcohol/heptane.  
Detection wavelength at 205 nm.  
Temperature at 35°C

30

- 11 -

Example 4

Savinase was tested for the ability to hydrolyse the lactam bond of racemic *cis*-2-acetyl-2-aza-bicyclo[2.2.1]hept-5-en-3-one enantioselectively. Reaction was carried out in a magnetically-stirred glass vial (4 ml working volume) containing 1 mg/ml of substrate in 50% tetrahydrofuran: 50% phosphate buffer (v/v) (50 mM, pH 7) at room temperature. Reaction was started by adding Savinase to a final concentration of 25 mg/ml. A flask with no enzyme served as control. Periodically, samples were removed and diluted 1:2 with water prior to hplc analyses.

**hplc:**

Column: Spherisorb C6 (15 x 0.46 cm).

Isocratic at 20°C at 1 ml/min.

Mobile phase: 5% (v/v) acetonitrile containing 0.1% (v/v) formic acid.

Detection wavelength at 210 nm.

**Chiral hplc:**

Column: Chiralpak AD (25 x 0.46 cm).

Isocratic at 20°C at 1 ml/min.

Mobile phase: 2% (v/v) ethanol/heptane.

Detection wavelength at 215 nm.


It was shown that, in the absence of enzyme, chemical hydrolysis of the substrate was negligible under reaction conditions. However, there was a significant non-enzymic hydrolysis of the substrate if tetrahydrofuran was omitted from reaction mixtures. Savinase hydrolysed racemic *cis*-2-acetyl-2-aza-bicyclo[2.2.1]hept-5-en-3-one enantioselectively to afford (-) (1R, 4S) 2-acetyl-2-aza-bicyclo[2.2.1]hept-5-en-3-one as evident by a negative sign of rotation by

- 12 -

chiralyser and by chiral hplc analysis. The reaction mixture, containing approximately 50% of the starting material was analysed by chiral hplc after two days and the residual lactam was shown, by comparison with an authentic sample, to have an enantiomeric excess of >99.8% with the correct absolute configuration for the synthesis of abacavir.


Claims:

1. A process for the preparation of substantially enantiomerically pure N-protected (1R,4S)-2-  
5 azabicyclo[2.2.1]hept-5-en-3-one of formula (IV)



wherein P is an activating and protecting group


- 15 wherein a racemic mixture of N-protected ( $\pm$ ) 2-azabicyclo[2.2.1]hept-5-en-3-one (V)



wherein P is an activating and protecting group

- 25 is treated with an acylase enzyme and the unreacted enantiomer of formula (IV) is isolated from the reaction mixture by conventional techniques.

- 30 2. A process for the enantiomeric resolution of a racemic mixture of N-protected ( $\pm$ ) 2-azabicyclo[2.2.1]hept-5-en-3-one (V)



- 14 -

wherein P is an activating and protecting group,

5 to yield substantially enantiomerically pure N-protected  
(1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one (IV) by  
treating the mixture with an acylase enzyme.

10 3. A process as claimed in claim 1 or claim 2 wherein  
P is an acyl or oxycarbonyl group.

4. A process as claimed in any of claims 1 to 3  
wherein P is a formyl or alkanoyl group having 1 to 4  
carbon atoms.

15 5. A process as claimed in any one of claims 1 to 3  
wherein P is an alkyloxycarbonyl or aralkyloxycarbonyl  
group.

20 6. A process as claimed in claim 5 wherein P is a tert  
butyloxycarbonyl or benzyloxycarbonyl group.

7. A process as claimed in any of the preceding claims  
wherein the acylase enzyme is derived from *Bacillus* sp.

25 8. A process as claimed in claim 7 wherein the acylase  
enzyme is Savinase.

30 9. A process as claimed in any of the preceding claims  
wherein the reaction is carried out in a mixture of  
organic solvent and water.

10. A process as claimed in claim 9 wherein the organic  
solvent is a water miscible organic solvent and less  
than 70% water by volume is used.

35 11. A process as claimed in claim 10 wherein the water  
miscible organic solvent is tetrahydrofuran or 1, 4-



- 15 -

dioxan.

12. A process as claimed in any of the preceding claims  
wherein the reaction is carried out within a pH range of  
5 6 to 11 and at a temperature of 20 to 50°C.

13. A process as claimed in claim 12 wherein the  
reaction is carried out at a pH of about 8 and a  
temperature of about 30°C.

10 14. A process as claimed in any of the preceeding  
claims wherein the unreacted N-protected (1R,4S)-2-  
azabicyclo[2.2.1]hept-5-en-3-one of formula (IV) is  
isolated by solvent extraction.

15

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/05291

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12P41/00 C12P13/00 C07D209/52

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12P C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EVANS C T ET AL: "POTENTIAL USE OF CARBOCYCLIC NUCLEOSIDES FOR THE TREATMENT OF AIDS CHEMO-ENZYMATIC SYNTHESIS OF THE ENANTIOMERS OF CARBOVIR." J CHEM SOC PERKIN TRANS I, (1992) 0 (5), 589-592. CODEN: JCPRB4. ISSN: 0300-922X., XP002089871 see the whole document	1
Y	EP 0 424 064 A (ENZYMATIX LTD) 24 April 1991 cited in the application see claims	1
Y	WO 92 18477 A (CHIRO LTD) 29 October 1992 see claims	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

13 January 1999

Date of mailing of the international search report

25/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Delanghe, L

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/05291

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NAKANO, HIROTO ET AL: "A facile lipase -catalyzed resolution of 2- azabicyclo '2.2.1! hept -5-en-3- ones" TETRAHEDRON: ASYMMETRY (1994), 5(7), 1155-6 CODEN: TASYE3;ISSN: 0957-4166, XP002089872 see the whole document -----	1
A	NAKANO, HIROTO ET AL: "Lipase -catalyzed resolution of 2- azabicyclo '2.2.1! hept -5-en-3- ones" TETRAHEDRON: ASYMMETRY (1996), 7(8), 2381-2386 CODEN: TASYE3;ISSN: 0957-4166, XP002089873 see the whole document -----	1

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/05291

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0424064 A	24-04-1991	AT 118208 T	15-02-1995
		DE 69016739 D	23-03-1995
		DE 69016739 T	14-06-1995
		DK 424064 T	26-06-1995
		ES 2067693 T	01-04-1995
		GR 3015887 T	31-07-1995
		JP 2648013 B	27-08-1997
		JP 3218380 A	25-09-1991
		US 5284769 A	08-02-1994
		US 5498625 A	12-03-1996
		US 5688933 A	18-11-1997
WO 9218477 A	29-10-1992	AU 1669792 A	17-11-1992